JG
TBPH icon

Joel Greenblatt’s Theravance Biopharma TBPH Stock Holding History

Joel Greenblatt’s Portfolio TBPH Stock Details TBPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-45,212
Closed -$734K – 1886
2026
Q1 		$734K Buy
45,212
+22,532
+99% +$399K ﹤0.01% 1393
2025
Q4 		$424K Buy
+22,680
New +$376K ﹤0.01% 1478
2017
Q1 		– Sell
-9,571
Closed -$305K – 1102
2016
Q4 		$305K Buy
+9,571
New +$297K ﹤0.01% 808
2016
Q1 		– Sell
-69,582
Closed -$733K – 1074
2015
Q4 		$733K Buy
+69,582
New +$1.1M 0.01% 647

Other funds holding TBPH

MAP
Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $9.54B AUM 55.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NM
Newtyn Management New York $801M AUM 23.14% 1-Year Est. Return
ICM
Irenic Capital Management New York $2.08B AUM 19.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Joel Greenblatt's TBPH Position: Q2 2026 in Review

Joel Greenblatt sold out of Theravance Biopharma (TBPH) in Q2 2026, closing a stake of 45,212 shares — an estimated $734K sold.

Joel Greenblatt first reported a position in TBPH in Q4 2015 and held it in 4 quarters. The position peaked at $734K in Q1 2026. 178 funds tracked by Wall St. Rank hold TBPH as of Q2 2026.

  • Joel Greenblatt reported no remaining Theravance Biopharma position as of Q2 2026 after selling out during the quarter.
  • Joel Greenblatt sold 45,212 Theravance Biopharma shares in Q2 2026, an estimated $734K.
  • Joel Greenblatt first reported a position in Theravance Biopharma in Q4 2015 and held it in 4 quarters.
  • Joel Greenblatt's Theravance Biopharma position peaked at $734K in Q1 2026.
  • 178 funds tracked by Wall St. Rank held Theravance Biopharma as of Q2 2026.

Based on Gotham Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.